WBB Securities Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: WBB Securities
Rating: 3
Author: MarketBeat

View the latest stock recommendations issued by analysts at WBB Securities. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from WBB Securities' equity research team. MarketBeat is not affiliated with or endorsed by WBB Securities.

1 Analyst
Updated 4/13/2026

Brokerage Ranking: Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Total Ratings: 7 Last 12 Months
Buy Ratings: 6 Last 12 Months
Sell Ratings: 0 Last 12 Months
Companies Covered: 4 Last 12 Months

Company	Current Price	Report Date	Analyst	Action	Price Target	Rating	Details
ENGN enGene	$1.91 +7.3%	4/13/2026	Karen Sterling Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$21.50	Buy	View details for WBB Securities rating of enGene (NASDAQ:ENGN) on 4/13/2026
OMER Omeros	$10.34 +11.4%	10/15/2025	Steve Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$45.00	Strong-Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 10/15/2025
CELU Celularity	$0.80 +29.1%	9/9/2025	Steve Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	$6.00	Hold ➝ Buy	View details for WBB Securities rating of Celularity (NASDAQ:CELU) on 9/9/2025
CELU Celularity	$0.80 +29.1%	8/18/2025	Steve Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$6.00	Moderate Buy	View details for WBB Securities rating of Celularity (NASDAQ:CELU) on 8/18/2025
MRKR Marker Therapeutics	$1.48 +0.7%	4/1/2025	Steve Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$12.50 ➝ $12.50	Strong-Buy	View details for WBB Securities rating of Marker Therapeutics (NASDAQ:MRKR) on 4/1/2025
OMER Omeros	$10.34 +11.4%	6/18/2021		Boost Price Target	$75.00 ➝ $100.00	Strong-Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 6/18/2021
ARCT Arcturus Therapeutics	$7.35 +1.0%	6/9/2020		Downgrade	$31.00	Buy ➝ Hold	View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 6/9/2020
ADMA ADMA Biologics	$9.16 +2.3%	4/4/2019		Upgrade		Buy	View details for WBB Securities rating of ADMA Biologics (NASDAQ:ADMA) on 4/4/2019
MRKR Marker Therapeutics	$1.48 +0.7%	3/29/2019		Upgrade	$7.29	Buy ➝ Strong-Buy	View details for WBB Securities rating of Marker Therapeutics (NASDAQ:MRKR) on 3/29/2019
ARCT Arcturus Therapeutics	$7.35 +1.0%	9/20/2018		Upgrade		Buy ➝ Strong-Buy	View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/20/2018
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
SRPT Sarepta Therapeutics	$19.18 -0.5%	6/20/2018		Reiterated Rating		Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 6/20/2018
ARCT Arcturus Therapeutics	$7.35 +1.0%	6/11/2018		Upgrade		Hold ➝ Buy	View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 6/11/2018
OMER Omeros	$10.34 +11.4%	3/26/2018		Reiterated Rating	$75.00	Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 3/26/2018
CLDX Celldex Therapeutics	$37.95 -1.1%	12/6/2017		Reiterated Rating	$150.00	Buy	View details for WBB Securities rating of Celldex Therapeutics (NASDAQ:CLDX) on 12/6/2017
ARCT Arcturus Therapeutics	$7.35 +1.0%	10/9/2017		Upgrade	$2.00	Hold ➝ Buy	View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 10/9/2017
LIVN LivaNova	$84.03 +0.5%	8/15/2017		Downgrade	$50.00	Hold ➝ Sell	View details for WBB Securities rating of LivaNova (NASDAQ:LIVN) on 8/15/2017
OMER Omeros	$10.34 +11.4%	6/14/2017		Reiterated Rating	$75.00	Strong-Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 6/14/2017
OMER Omeros	$10.34 +11.4%	3/30/2017		Reiterated Rating	$75.00	Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 3/30/2017
OMER Omeros	$10.34 +11.4%	11/17/2016	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$75.00	Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 11/17/2016
ARCT Arcturus Therapeutics	$7.35 +1.0%	11/2/2016		Upgrade	$4.00 ➝ $1.90	Sell ➝ Hold	View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 11/2/2016
OMER Omeros	$10.34 +11.4%	10/17/2016	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$75.00	Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 10/17/2016
SCYX SCYNEXIS	$4.73 +6.8%	10/7/2016		Upgrade	$640.00	Buy ➝ Strong-Buy	View details for WBB Securities rating of SCYNEXIS (NASDAQ:SCYX) on 10/7/2016
SRPT Sarepta Therapeutics	$19.18 -0.5%	9/20/2016	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$40.00 ➝ $60.00	Strong-Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 9/20/2016
ARCT Arcturus Therapeutics	$7.35 +1.0%	9/12/2016		Downgrade	$5.00 ➝ $4.00	Hold ➝ Sell	View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/12/2016
LIVN LivaNova	$84.03 +0.5%	8/31/2016		Reiterated Rating	$60.00	Hold	View details for WBB Securities rating of LivaNova (NASDAQ:LIVN) on 8/31/2016
SCYX SCYNEXIS	$4.73 +6.8%	8/9/2016		Upgrade	$640.00	Speculative Buy ➝ Buy	View details for WBB Securities rating of SCYNEXIS (NASDAQ:SCYX) on 8/9/2016
OMER Omeros	$10.34 +11.4%	6/14/2016		Reiterated Rating	$75.00	Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 6/14/2016
SRPT Sarepta Therapeutics	$19.18 -0.5%	6/8/2016	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$40.00	Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 6/8/2016
SRPT Sarepta Therapeutics	$19.18 -0.5%	5/2/2016	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$40.00	Strong-Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 5/2/2016
SRPT Sarepta Therapeutics	$19.18 -0.5%	4/26/2016	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$40.00	Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 4/26/2016
SRPT Sarepta Therapeutics	$19.18 -0.5%	3/30/2016	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$40.00	Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 3/30/2016
TZOO Travelzoo	$11.76 +0.9%	2/17/2016		Initiated Coverage	$11.00	Speculative Buy	View details for WBB Securities rating of Travelzoo (NASDAQ:TZOO) on 2/17/2016
SCYX SCYNEXIS	$4.73 +6.8%	1/4/2016	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$640.00	Buy	View details for WBB Securities rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2016
SCYX SCYNEXIS	$4.73 +6.8%	12/29/2015		Initiated Coverage	$640.00	Buy	View details for WBB Securities rating of SCYNEXIS (NASDAQ:SCYX) on 12/29/2015
SRPT Sarepta Therapeutics	$19.18 -0.5%	11/22/2015	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$40.00	Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/22/2015
CTSO Cytosorbents	$0.43 +10.3%	10/29/2015		Upgrade	$13.00	Speculative Buy ➝ Buy	View details for WBB Securities rating of Cytosorbents (NASDAQ:CTSO) on 10/29/2015
OMER Omeros	$10.34 +11.4%	8/18/2015		Reiterated Rating	$60.00	Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 8/18/2015
OMER Omeros	$10.34 +11.4%	8/18/2015		Boost Price Target	$60.00 ➝ $75.00	Strong-Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 8/18/2015
SRPT Sarepta Therapeutics	$19.18 -0.5%	8/13/2015	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$35.00 ➝ $40.00	Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 8/13/2015
ARCT Arcturus Therapeutics	$7.35 +1.0%	8/9/2015		Reiterated Rating	$5.00	Hold	View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/9/2015
Amazon, Google, Meta, and Microsoft just committed $700 billion (Ad) Amazon, Google, Meta, and Microsoft have committed $700 billion to AI infrastructure in 2026 alone - more than the entire dot-com buildout combined. When Zuckerberg told investors 'we want to make sure we're not underinvesting,' veteran Wall Street analyst Chris Rowe says that wasn't a growth pitch - it was fear. That money flows downstream through chipmakers, network builders, and small data infrastructure companies most investors have never heard of. Rowe spent 30 years tracking institutional money before it moves, and he says this spending won't stop regardless of market conditions - none of these four can afford to be the one who blinked. See Chris Rowe's full breakdown of where this money is headed
ARCT Arcturus Therapeutics	$7.35 +1.0%	6/24/2015		Downgrade	$5.00	Speculative Buy ➝ Hold	View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 6/24/2015
CLDX Celldex Therapeutics	$37.95 -1.1%	6/1/2015	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$450.00 ➝ $600.00	Buy	View details for WBB Securities rating of Celldex Therapeutics (NASDAQ:CLDX) on 6/1/2015
SRPT Sarepta Therapeutics	$19.18 -0.5%	5/22/2015	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$25.00 ➝ $35.00	Strong-Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 5/22/2015
CTSO Cytosorbents	$0.43 +10.3%	2/25/2015		Initiated Coverage	$13.00	Speculative Buy	View details for WBB Securities rating of Cytosorbents (NASDAQ:CTSO) on 2/25/2015
SRPT Sarepta Therapeutics	$19.18 -0.5%	1/15/2015	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating		Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 1/15/2015
SRPT Sarepta Therapeutics	$19.18 -0.5%	11/26/2014	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	$25.00	Buy ➝ Strong-Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/26/2014
SRPT Sarepta Therapeutics	$19.18 -0.5%	7/29/2014	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Price Target	$25.00	Speculative Buy ➝ Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 7/29/2014
SRPT Sarepta Therapeutics	$19.18 -0.5%	7/29/2014	Stephen Brozak Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Speculative Buy ➝ Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 7/29/2014
ARCT Arcturus Therapeutics	$7.35 +1.0%	6/26/2014		Initiated Coverage	$18.00	Hold	View details for WBB Securities rating of Arcturus Therapeutics (NASDAQ:ARCT) on 6/26/2014
OMER Omeros	$10.34 +11.4%	4/7/2014		Boost Price Target	$20.00 ➝ $30.00	Strong-Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 4/7/2014
SRPT Sarepta Therapeutics	$19.18 -0.5%	11/26/2013		Upgrade	$9.00 ➝ $19.00	Sell ➝ Speculative Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/26/2013
PATH UiPath	$11.82 +0.9%	1/22/2013		Upgrade	$7.00	Buy ➝ Strong-Buy	View details for WBB Securities rating of UiPath (NYSE:PATH) on 1/22/2013
SRPT Sarepta Therapeutics	$19.18 -0.5%	9/12/2012		Downgrade	$8.00 ➝ $9.00	Hold ➝ Sell	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 9/12/2012
BCRX BioCryst Pharmaceuticals	$10.17 +3.4%	8/14/2012		Downgrade	$8.50 ➝ $4.40	Buy ➝ Hold	View details for WBB Securities rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) on 8/14/2012
SRPT Sarepta Therapeutics	$19.18 -0.5%	8/9/2012		Initiated Coverage	$8.00	Buy ➝ Hold	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 8/9/2012
VCEL Vericel	$46.56 -0.9%	7/24/2012		Upgrade	$3.00 ➝ $3.00	Buy ➝ Strong-Buy	View details for WBB Securities rating of Vericel (NASDAQ:VCEL) on 7/24/2012
VCEL Vericel	$46.56 -0.9%	6/4/2012		Upgrade	$3.00	Speculative Buy ➝ Buy	View details for WBB Securities rating of Vericel (NASDAQ:VCEL) on 6/4/2012
VCEL Vericel	$46.56 -0.9%	4/16/2012		Upgrade	$2.50 ➝ $3.00	Hold ➝ Speculative Buy	View details for WBB Securities rating of Vericel (NASDAQ:VCEL) on 4/16/2012
OMER Omeros	$10.34 +11.4%	3/22/2012		Boost Price Target	$10.50 ➝ $20.00	Strong-Buy	View details for WBB Securities rating of Omeros (NASDAQ:OMER) on 3/22/2012
JAZZ Jazz Pharmaceuticals	$244.17 +0.3%	12/8/2011		Downgrade	$15.00 ➝ $40.00	Buy ➝ Hold	View details for WBB Securities rating of Jazz Pharmaceuticals (NASDAQ:JAZZ) on 12/8/2011
VCEL Vericel	$46.56 -0.9%	12/6/2011		Upgrade	$2.00 ➝ $2.50	Sell ➝ Hold	View details for WBB Securities rating of Vericel (NASDAQ:VCEL) on 12/6/2011
GERN Geron	$1.44 +5.9%	11/16/2011		Downgrade	$19.00 ➝ $6.00	Strong Buy ➝ Buy	View details for WBB Securities rating of Geron (NASDAQ:GERN) on 11/16/2011
MBOT Microbot Medical	$1.93 +1.0%	7/7/2011		Initiated Coverage	$36.00	Sell	View details for WBB Securities rating of Microbot Medical (NASDAQ:MBOT) on 7/7/2011
EBS Emergent Biosolutions	$8.18 -1.2%	5/31/2011		Boost Price Target	$20.50 ➝ $30.00	Strong Buy	View details for WBB Securities rating of Emergent Biosolutions (NYSE:EBS) on 5/31/2011
PLX Protalix BioTherapeutics	$2.30 -0.9%	3/17/2011		Downgrade	$100.00	Strong-Buy ➝ Buy	View details for WBB Securities rating of Protalix BioTherapeutics (NYSE:PLX) on 3/17/2011
VCEL Vericel	$46.56 -0.9%	2/9/2011		Initiated Coverage	$2.00	Sell	View details for WBB Securities rating of Vericel (NASDAQ:VCEL) on 2/9/2011
OSIR Osiris Therapeutics	$18.99	1/31/2011		Downgrade	$5.00 ➝ $5.00	Sell ➝ Sell Short	View details for WBB Securities rating of Osiris Therapeutics (OTCMKTS:OSIR) on 1/31/2011
SVA Sinovac Biotech	$6.47	1/4/2011		Downgrade	$7.50 ➝ $7.50	Buy ➝ Speculative Buy	View details for WBB Securities rating of Sinovac Biotech (NASDAQ:SVA) on 1/4/2011
SRPT Sarepta Therapeutics	$19.18 -0.5%	12/29/2010		Initiated Coverage	$3.00	Speculative Buy	View details for WBB Securities rating of Sarepta Therapeutics (NASDAQ:SRPT) on 12/29/2010

MarketBeat Community Rating for WBB Securities

MarketBeat's community ratings are surveys of what our community members think about WBB Securities and other research firms in the last 90 days. Vote "Outperform" if you believe WBB Securities's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe WBB Securities's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.

COMMUNITY RATINGS: 3.0out of 5 (last 90 days)
3 of 5 stars
OUTPERFORM VOTES: 6 Believe will outperform the market
UNDERPERFORM VOTES: 4 Believe will underperform the market

Analysts at WBB Securities

WBB Securities' equity research team has issued ratings on 4 companies across 1 sectors over the past 12 months, covered by 1 analyst. The WBB Securities analysts below are listed by number of ratings issued in the last year.

Steve Brozak
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
5 Ratings

WBB Securities Stock Coverage by Sector

WBB Securities concentrates its research most heavily in Medical (100.0%). The chart below shows how WBB Securities' 4 rated companies are distributed across all 1 sector it covers.

Medical
4 companies
100.0%

Best & Worst Calls

Best Call
000000.0%
NASDAQ:CDTX
Boost Price Target • Dec 5, 2024
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
NASDAQ:CLDX
Reiterated Rating • Dec 6, 2017
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Similarly Rated Firms

WBB Securities - Frequently Asked Questions

WBB Securities' analysts currently have buy-equivalent ratings on 4 companies.

WBB Securities has the deepest coverage in Medical (100.0% of rated companies).

WBB Securities issued 7 ratings over the last 12 months across 4 companies â€” an average of roughly 1 rating actions per month. These include boost price target, initiated coverage, reiterated rating and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current WBB Securities analyst actions.

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?